Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount

Abstract

The (111)In-DOTA-Z(EGFR:2377) Affibody molecule is a promising tracer for radionuclide molecular imaging of EGFR expression in malignant tumours. Careful optimization of protein dose is required for high-contrast imaging of EGFR expression in vivo.

Imaging of Platelet-Derived Growth Factor Receptor β Expression in Glioblastoma Xenografts Using Affibody Molecule111In-DOTA-Z09591

“…Therefore, we were concerned that it might be challenging to obtain a sufficient contrast for imaging the PDGFRb overexpressing tumor in mice using a tracer that binds both human and murine PDGFRb. Increasing the injected dose of unlabeled protein may provide preferential block of binding to normal tissues with low antigen density (39). This requires that the receptor density is higher in the tumor, sufficiently high to avoid PDGFRb saturation at a protein concentration providing low uptake in normal tissues.…”

Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications

“…The development of Affibody molecules for molecular imaging applications was primarily performed with different HER2-binding Affibody molecules. The knowledge obtained from this work was later applied also for development of EGFR-and PDGFRb-binding Affibody molecules [30] (unpublished). Fig.…”

Incorporation of a Triglutamyl Spacer Improves the Biodistribution of Synthetic Affibody Molecules Radiofluorinated at the N-Terminus via Oxime Formation with 18F-4-Fluorobenzaldehyde

“…Currently, Affibody molecules with low nanomolar or subnanomolar affinity to several RTKs, e.g. HER2 8 , EGFR 9 , HER3 10 , PDGFR  and IGF1R 12 , have been developed. Radiolabeled derivatives of the anti-HER2 Z HER2:342 Affibody molecule have demonstrated the capacity of high contrast imaging of HER2-expressing tumors a few hours after injection both in preclinical studies 13 and in clinical trials 14,15 .…”